Thrombocytes (platelets, PLTs) circulate in the peripheral blood and act as an integral element of haemostasis. Low platelet numbers lead to symptoms such as petechial bleeding, bruising or the risk of severe bleeding. Reasons for decreased platelet numbers in the peripheral blood can be either decreased platelet production [e.g. in aplastic anaemia (AA), myelodysplastic syndromes (MDSs), other neoplastic diseases, recent cytostatic chemotherapy], or platelet consumption [e.g. in immune thrombocytopenia (ITP) or microangiopathic diseases].
Measurement of reticulocytes as immature erythrocytes (red blood cells, RBC) for the clinical distinction between production deficit and cell destruction or loss is well established. Similarly, newly released platelets in the circulation can be distinguished from mature platelet by their RNA content, which is lost later on. These newly produced platelets are termed immature (imPLT) or reticulated. They are assumed to be a surrogate marker of thrombopoietic activity in analogy to reticulocytes. To use this fact for clinical decision-making, since the 1990s, several studies using flow cytometry with different fluorescent dyes have shown that the amount of reticulated platelets reflects the rate of thrombopoiesis, but standardization remained difficult (Kienast & Schmitz, 1990; Ault et al, 1992; Richards & Baglin, 1995; Matic et al, 1998) . Later on, Sysmex (Kobe, Japan) introduced the immature platelet fraction (IPF), measured by a haematology analyser based on RNA staining as a routine parameter within the automated blood count (Briggs et al, 2004) . A few years later, Abbott Diagnostics (Santa Clara, CA, USA) also introduced a method to quantify immature platelets based on RNA staining as part of the automated blood count, called reticulated platelets (rPT) (Hoffmann et al, 2013) . For convenience, from here on, we will use the term imPLT for immature or reticulated platelets determined by any method and either IPF or rPT when referring to the method of one specific manufacturer.
In a number of reports, the clinical usefulness of imPLT determination with analysers produced by Sysmex or Abbott as well as by custom-made flow cytometry was tested for different clinical situations. In several reports, elevated imPLT compared to controls were described for patients with ITP and other conditions with enhanced peripheral platelet destruction, e.g. thrombotic thrombocytopenic purpura or disseminated intravascular coagulation, and for patients recovering after chemotherapy (Briggs et al, 2004; Abe et al, 2006; Kickler et al, 2006; Jung et al, 2010; Meintker et al, 2013) . However, elevated imPLT were also measured in situations with bone marrow suppression and decreased platelet production (Saigo et al, 2009; Sugimori et al, 2009; Jung et al, 2010; Meintker et al, 2013) . Thus we undertook a study to directly test the clinical relevance of imPLT measurements in thrombocytopenic patients as they might appear in the clinic and determine if imPLT measurements can discriminate between ITP versus bone marrow failure (BMF) due to acute myeloid leukaemia (AML), MDS or AA with two different analysers, the Sysmex XE-5000 and the Abbott CD Sapphire. To our knowledge, this is the largest study to prospectively compare imPLT in patients with ITP with a well-defined cohort of BMF patients excluding chemotherapy-induced BMF, and the first study to perform such a side-by-side investigation with a CD Sapphire.
Methods

Patients
Patients with a platelet count less than 70 9 10⁹/l caused either by BMF or ITP were included after obtaining informed consent. Patients could be included twice, if an interval of at least 1 month had passed between the two measurements. In case of missing timely informed consent in outpatients, samples could be included after complete anonymization.
The following additional criteria had to be fulfilled for inclusion of patients: Unequivocal diagnosis, exclusion of EDTA-induced pseudothrombocytopenia and no platelet transfusions in the preceding 48 h before blood sample collection. BMF patients were included with a diagnosis of AML, MDS or AA (lymphatic neoplasia was excluded, because it may be accompanied by ITP). ITP was diagnosed in accordance with consensus criteria (Provan et al, 2010) . Patients were either steroid-responsive at follow-up or diagnosis was confirmed by bone marrow examination. No treatment with chemotherapy in the previous 3 months or immunosuppressive drugs in the previous month was allowed for BMF patients. ITP could be included either at diagnosis or during treatment as long as the platelet count was below 70 9 10 9 /l.
In addition, presumably healthy controls with a platelet count of more than 150 9 10⁹/l and without abnormalities in their blood counts were evaluated as reference. Samples from these subjects were completely anonymized. All procedures were performed with blood drawn for routine purposes. For selected additional analyses, data from an earlier study (Meintker et al, 2013) were included. The study was approved by the local ethics committee of the University of Erlangen.
Measurements
Prior to the measurements, all samples were labelled with unique barcode identifiers, stored at room temperature and measured within 6 h of blood collection. Samples were analysed in duplicate with both the CD Sapphire (Abbott Diagnostics) and XE-5000 (Sysmex) haematology analysers. Both haematology analysers were run in accordance with the standard operating procedures as routine instruments at the laboratories of the Department of Haematology/Oncology (Abbott) and the Department of Transfusion Medicine and Haemostaseology (Sysmex) at the University Hospital of Erlangen and were reviewed with quality check samples twice daily.
Impedance and optical scatter methods are used by both analysers for platelet measurements. To incorporate imPLT in the automated blood count, both manufacturers use flow cytometry with fluorescent dyes, which penetrate the cell membrane and stain the RNA in imPLT. Practical details are different in the two analysers. In the XE-5000, a fixed gate is applied to discriminate mature and imPLT by forward scatter and fluorescence intensity. IPF is characterized as the fraction of platelets with large size and high fluorescence intensity (Briggs et al, 2004) . The CD Sapphire records three angles of light scatter and fluorescence as part of its reticulocyte assay and generates a variable gate in the fluorescence versus 7°p lot, which allows for correcting the size-dependent background fluorescence. The result is given as percentage of reticulated platelets (rPT), corresponding to imPLT (Hoffmann et al, 2013) .
Statistical analysis
The precision of duplicate measurements from each instrument was analysed by Pearson's correlation coefficient and calculating repeatability using the standard deviation (SD) of differences of double measurements, as suggested by Bland and Altman (1999) . Due to the bimodal distribution of platelet measurements, precision was determined separately for normal and thrombocytopenic samples. Similarly, interinstrument agreement was tested by correlation and BlandAltman analysis. To check statistically significant differences between different cohorts, the Mann Whitney test was applied. For the determination of the clinical usefulness to separate ITP from BMF, all possible cut-off levels with associated sensitivity and specificity were assigned and plotted in receiver operating characteristic (ROC) curves and the area under the curve (AUC) was calculated. 
Results
Patients
We collected 213 blood samples for inclusion in our study. In five control samples measured on one single calendar day, duplicate platelet measurements from Abbott CD Sapphire were strongly diverging, indicating technical problems. These samples were thus omitted from further analysis. In 11 patient samples, the aetiology of thrombocytopenia could not be definitely confirmed (e.g., due to dysplastic features in the bone marrow of putative ITP patients). Five patients were erroneously included despite receiving platelet transfusions less than 2 days before blood sampling. These 16 samples were excluded from further disease-specific analysis whereas the total amount of 208 blood samples was used for precision analyses. We obtained 55 samples from 53 different BMF patients, 45 samples from 36 different patients with ITP and 92 samples from presumably healthy controls. Characteristics of patients and treatments are shown in Table I . Median platelet counts were 252 9 10 9 /l in controls, 28 9 10 9 /l in BMF patients and 20 9 10 9 /l in ITP patients with a comparable distribution of platelet counts between BMF and ITP ( Figure S1 ).
Precision of measurements and instrument comparison
As in our previous report, a high precision (repeatability) for duplicate measurements of platelets was obtained (Meintker et al, 2013) . For the Sysmex XE-5000 we calculated a correlation of r 2 = 0Á987 and SD of difference [SD(D)] of dual measurements (Bland & Altman, 1999 ) of 5Á8 9 10 9 /l in controls. In thrombocytopenic samples the correlation was r 2 = 0Á964 and SD(D) was 3Á6 9 10 9 /l. Using Abbott CD Sapphire, the corresponding results were r 2 = 0Á99 and SD (D) of 5Á0 9 10 9 /l in controls and r 2 = 0Á99 and SD(D) of 1Á9 9 10 9 /l in thrombocytopenic samples. Inter-instrument comparison showed slight, mostly non-systematic differences between both analysers: in controls we calculated a correlation of r 2 = 0Á95 and SD(D) of 11Á2 9 10 9 /l with slightly lower platelet measurements with the XE-5000 (bias À2Á7 9 10 9 /l) and in thrombocytopenic samples a correlation of r 2 = 0Á91 and SD(D) of 5Á7 9 10 9 /l with minimally higher platelet measurements (bias 1Á7 9 10 9 /l) with the XE-5000. IPF measurements were obtained for all samples with the XE-5000. One rPT measurement in the BMF group and five rPT measurements in the ITP group could not be performed by the CD Sapphire. XE-5000 showed acceptable repeatability with a SD(D) of 3Á4% and a correlation of r 2 = 0Á89 in the total cohort, SD(D) of 0Á48% and r 2 = 0Á91 in the healthy controls, and SD(D) of 4Á5% and r 2 = 0Á83 in thrombocytopenic samples. With CD Sapphire we observed inferior repeatability with a SD(D) of 3Á3% and r 2 = 0Á73 in the total cohort, 1Á0% and r 2 = 0Á35 in the healthy controls, and 11Á9% and a correlation of r 2 = 0Á53 in thrombocytopenic samples.
Inter assay comparison between two types of haematology instruments for imPLT measurements showed a poor correlation of r 2 = 0Á18 (nevertheless significantly different from zero, P < 0Á0001). In the Bland-Altman plot to describe inter-method bias, the difference of IPF(XE-5000) -rPT(CD Sapphire) is plotted against mean imPLT of both analysers. Overall, XE-5000 measured higher imPLT values than CD Sapphire with larger differences in samples with higher imPLT (Fig 1) .
Immature platelets in different patient groups
In control specimens we measured median IPF of 2Á6% (95% range from 0Á9% to 8Á5%) with XE-5000 and median rPT of 1Á8% (95% range from 0Á5% to 4Á6%) with CD Sapphire, similar to our earlier report (Meintker et al, 2013) . In both patient groups we observed increased fractions of imPLT as compared to healthy controls (Fig 2A) . With XE-5000, IPF was significantly (P = 0Á0004) higher in ITP (median IPF 16Á2%, 95% range 2Á6-45Á9%) as compared to BMF (9Á9%, 95% range 2Á4-34Á1%), however, a broad overlap between both cohorts and a smaller overlap with healthy controls was observed. In contrast, the median rPT of 10Á9% (95% range, 2Á9-23Á4%) in patients with BMF measured by CD Sapphire is similar to the median rPT of 9Á1% (95% range, 1Á4-20Á5%) in patients with ITP, thus providing no useful diagnostic information to separate the two groups (Fig 2B) . In an exploratory analysis, we compared newly diagnosed ITP patients before start of therapy, other patients without recent therapy and ITP patients during active therapy and found a broad scatter of measurements without significant differences between subgroups with both analysers ( Figure S2 ). Similarly, there were no significant differences between imPLT in AA, AML and MDS (not shown). Considering the findings described above, we performed ROC curve analysis to check the clinical usefulness of IPF measurements for the discrimination of ITP versus BMF for the XE-5000. The explanatory power to discriminate BMF from ITP in thrombocytopenic patients was only moderate, with an AUC of 0Á71 (Fig 3) .
Given that the considerably elevated imPLT compared to normal controls in the BMF group were somewhat unexpected, we further analysed the relationship between platelet counts and imPLT. With both analysers, we observed a significant correlation between lower platelets and increased imPLT in thrombocytopenic samples. The slope of the regression of IPF versus platelets as measured by the XE-5000 was À0Á15 for BMF samples (significantly different from zero, P = 0Á002) and À0Á07 for ITP samples (not significant) (Fig 4) . With the CD Sapphire, the slope of the regression of rPT versus platelets was À0Á07 for BMF samples (P = 0Á06) and À0Á13 for ITP samples (P = 0Á006). In order to determine whether this is a general phenomenon, we analysed data from patients with chemotherapy-induced thrombocytopenia from our previous study (Meintker et al, 2013) and observed a similar correlation between low platelet count and higher imPLT. Merging the cohorts, correlation was statistically highly significant (not shown in detail). The slope in normal samples was slightly negative with the XE-5000 and slightly positive with the CD Sapphire (Fig 4) .
This increase of imPLT with decreasing platelets may indicate an earlier release of imPLT into the circulation in the state of thrombocytopenia, thus decreasing the diagnostic value of imPLT measurements by both analysers. Nevertheless, with the XE-5000 we still observed a highly significant difference between ITP and BMF, whereas this did not hold true for the CD Sapphire. We reasoned, that these discrepant results might be explained by the different effect of platelet size on imPLT measurements in the two analysers. Thus we investigated the mean platelet volume (MPV) in our different cohorts. Using the CD Sapphire, we observed significantly larger platelets in ITP compared to BMF and also in both patient groups compared to controls (Fig 5) . The difference in MPV between ITP and BMF was large enough to be used as a diagnostic parameter to discriminate the two clinical situations. Constructing a ROC curve, we obtained an AUC of 0Á74 (Fig 3B) . MPV measurements were not possible with the XE-5000 in the majority of thrombocytopenic samples due to inability of this analyser to determine this parameter with very low platelet counts. However, larger MPV was also measured in ITP compared to BMF with XE-5000 in samples in which this parameter could be determined (not shown in detail).
Discussion
In the present study, as expected, both haematology analysers detected elevated fractions of imPLT as compared to normal controls in patients with ITP. However, imPLT were also considerably increased in patients with BMF, leading to only limited discriminatory power to separate ITP from BMF with the Sysmex XE-5000. The CD Sapphire was not able to distinguish ITP from BMF by the use of rPT measurements at all.
Increased levels of imPLT in situations of decreased platelet production in the bone marrow have already been shown (Saigo et al, 2009; Sugimori et al, 2009; Jung et al, 2010; Pons et al, 2010; Meintker et al, 2013) , with Pons et al (2010) showing this phenomenon in a small cohort using two different methods, i.e. IPF by a Sysmex XE analyser and custom-made flow cytometry of platelets. In two reports, the authors speculate that high imPLT in MDS may be linked to different clinical subtypes; however, patient numbers are too small to firmly establish this fact (Saigo et al, 2009; Sugimori et al, 2009) . In order to prospectively evaluate the diagnostic relevance of imPLT measurements in the situation of thrombocytopenia of unknown aetiology, our study was performed with well-defined cohorts of thrombocytopenic patients, excluding any patient with an ambiguous diagnosis. Furthermore, recent platelet transfusions were excluded, as this treatment may decrease imPLT values (Bat et al, 2013; Meintker et al, 2016, in press) , which is especially relevant for BMF patients, because this patient group is transfused more frequently.
Regarding our results with increased imPLT in many BMF patients, we reasoned that this might be a phenomenon of accelerated release of imPLT into the circulation, which is driven by a state of low platelet counts. In fact, we observed a reverse correlation between low platelet counts and increased imPLT in thrombocytopenia of any cause (Fig 4) . An inverse correlation was also observed within normal samples with the XE-5000, whereas rPT (CD Sapphire) increased with high-normal platelet counts in accordance with published results (Hoffmann et al, 2013; see discussion below) . This is similar to the situation in erythropoiesis, where we know from early studies that more immature forms of reticulocytes are released into the circulation in anaemia and thus the time of reticulocytes to lose their reticulum -the "reticulocyte lifespan" -is increased (Hillman, 1969) , a phenomenon called "reticulocyte shift". This reticulocyte shift has to be taken into account by calculation of the "reticulocyte production index" (Liesveld et al, 1987) , if the reticulocyte count is clinically assessed, making this index more meaningful than the mere reticulocyte percentage. A similar shift to more imPLT in the situation of severe thrombocytopenia was shown in animal experiments (Ang enieux et al, 2016) , indicating, that the inverse correlation between platelet counts and imPLT may be in part explained by a similar "imPLT shift".
Whereas such a shift of imPLT into the circulation with elevated imPLT measurements in patients with BMF is probably one factor to reduce the clinical usefulness of imPLT for the distinction between ITP and BMF, a second factor is the multi-causative pathogenesis of ITP in which enhanced destruction of platelets is only one component. ITP is considered to be caused by autoantibodies leading to platelet destruction with decreased platelet lifespan and increased platelet turnover in many patients; however, platelet turnover may also be normal or even decreased in ITP (Heyns et al, 1986; Ballem et al, 1987; Strom, 2015) . Accordingly, it was shown that autoantibodies, including anti-glycoprotein (GP) IIb/IIIa and/or anti-GPIb/IX autoantibodies, in the plasma of ITP patients interfere with platelet production by megakaryocytes (Chang et al, 2003; McMillan et al, 2004) . Thus, in most ITP patients, thrombocytopenia results from platelet destruction in the periphery plus decreased platelet production in the bone marrow (Kashiwagi & Tomiyama, 2013) .
These pathophysiological facts explain why imPLT measurements are not an ideal tool to distinguish ITP from BMF. IPF measured by the Sysmex XE-5000 still contained some diagnostic relevance, whereas rPT measured by the Abbott CD Sapphire did not. One probable reason for this discrepancy is the different gating strategies in these analysers. Large platelets are more easily gated as immature with the XE-5000, because this analyser uses an absolute threshold of fluorescence intensity (Briggs et al, 2004) , whereas the threshold of the CD Sapphire is corrected for size-dependent background staining (Hoffmann, 2014) . This also explains the different results regarding the correlation between imPLT and platelet count within the normal range, since average MPV decreases with increasing platelet count (Hoffmann et al, 2013) . The theoretical advantage of the Abbott method may thus be a disadvantage if it comes to separating ITP from BMF, given that average platelet size is larger in ITP than in BMF (Fig 5) . Parameters of platelet size have been reported to be of value for distiguishing ITP from BMF (Kaito et al, 2005; Numbenjapon et al, 2008) . In our patient cohort, MPV was of limited diagnostic power (Fig 3B) , which is in accordance with reports from other groups (Abe et al, 2006; Xu et al, 2013) .
In summary, our data, obtained from well-defined prospectively selected patient cohorts, show only limited clinical value of imPLT measurements to separate ITP from diagnoses with BMF, which is explained by two pathophysiological mechanisms: Firstly, imPLT are increased in patients with low platelet count independent of underlying diseases, most probably due to an "imPLT shift" in analogy to the well-known reticulocyte shift in erythrocytes. Secondly, ITP is a disease not only of platelet destruction but also of corrupt megakaryopoiesis with variable contribution of both components to the degree of thrombocytopenia. Given that the factors described above may be present to a variable degree in different patient cohorts, this may partly explain why divergent estimations of the predictive value of imPLT measurements are reported in the literature. Furthermore, different implementations by the manufacturers lead to disparate results. In our study, rPT measurements by the Abbott CD Sapphire were of no clinical value at all, whereas the IPF determined the by Sysmex XE-5000 carried significant diagnostic information. Recently, Sysmex introduced the new XN-Series with a novel PLT-F-channel, which enables more accurate counts of platelets and IPF. XN analysers were reported to be more useful for the separation of IPT from BMF (Sakuragi et al, 2015) . Nevertheless, we assume that the overlap of imPLT measurements in ITP and BMF patients is also a biological phenomenon and cannot be completely overcome by improved technical procedures.
